uniQure NV (QURE) (Q3 2026) Earnings Call Highlights: FDA Priority Review for AMT-130 and a ...
UniQure NV (NASDAQ:QURE) Q3 Revenue Miss Overshadows EPS Beat and Huntington’s Regulatory Progress
uniQure Q3 EPS $(0.88) Beats $(0.92) Estimate, Sales $5.200M Miss $6.178M Estimate
uniQure: The Market May Be Misreading The AMT-130 Four-Year Data (Rating Upgrade)
Loading...